Amorfix Collaborates with Columbia University on Potential ALS Therapeutic

Approximately 20% of inherited ALS cases are caused by the misfolding of mutant SOD1 proteins. To prevent the toxicity of these misfolded proteins, Amorfix Life Sciences Ltd. developed anti-SOD1 antibodies that target and bind to misfolded SOD1. However, the details of how the antibodies are working to prevent toxicity at the cellular level are still unknown. To determine how these antibodies work, Amorfix turned to Dr. Serge Przedborski at Columbia University. Dr. Neil Cashman, Amorfix’s Chief Scientific Officer and founder, said “This collaboration is designed to help answer key questions about the pivotal role of misfolded SOD1 in ALS. Understanding the disease from a mechanistic perspective will greatly facilitate the development of new treatments that can effectively treat ALS patients and hopefully prevent further decline in neurological function.” Biogen Idec is currently licensing Amorfix’s anti-SOD1 antibodies to pursue the development of antibody-based ALS therapeutics.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail